Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Birabresib - OncoEthix

Drug Profile

Birabresib - OncoEthix

Alternative Names: MK 8628; OTX 015; Y-803

Latest Information Update: 28 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Merck & Co; Mitsubishi Tanabe Pharma Corporation; OncoEthix
  • Class 3-ring heterocyclic compounds; Antineoplastics; Azepines; Small molecules; Triazoles
  • Mechanism of Action BRD2 protein inhibitors; BRD3 protein inhibitors; BRD4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I/II Glioblastoma
  • No development reported Haematological malignancies
  • Discontinued Crohn's disease; Ulcerative colitis

Most Recent Events

  • 28 Jan 2019 No recent reports of development identified for phase-I development in Haematological-malignancies in France (PO)
  • 28 Jan 2019 No recent reports of development identified for phase-I development in Haematological-malignancies in Italy (PO)
  • 28 Jan 2019 No recent reports of development identified for phase-I development in Haematological-malignancies in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top